Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687980 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
A Phase 3 study of Lichen Simplex Chronicus, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT06687980: Active Phase 3 study of Lichen Simplex Chronicus, sponsored by Sanofi.
NCT06687980 is a Phase 3 study of Lichen Simplex Chronicus that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 138 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06687980, a Phase 3 study of Lichen Simplex Chronicus, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Primary Outcome
Worst-Itch numerical rating score (WI-NRS) is a patient report outcome (PRO) comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (20)
Other
- Investigational Site Number : 0320201 - Buenos Aires
- Investigational Site Number : 0320203 - Córdoba
- Investigational Site Number : 0560202 - Alken
- Investigational Site Number : 0560203 - Maldegem
Texas
- Bellaire Dermatology Associates,- Site Number : 8400202 - Bellaire
- Austin Institute for Clinical Research - Pflugerville- Site Number : 8400203 - Pflugerville
- Progressive Clinical Research - San Antonio- Site Number : 8400206 - San Antonio
California
- Cosmetic Dermatology of Orange County- Site Number : 8400232 - Anaheim
- Center for Dermatology Clinical Research- Site Number : 8400226 - Fremont
Florida
- University of Miami Miller School of Medicine- Site Number : 8400218 - Miami
- TrueBlue Clinical Research- Site Number : 8400208 - Tampa
Alberta
- Investigational Site Number : 1240210 - Calgary
- Investigational Site Number : 1240207 - Edmonton
Georgia
- Skin Care Physicians of Georgia - Macon- Site Number : 8400236 - Macon
Indiana
- Southern Indiana Clinical Research Center- Site Number : 8400230 - Columbus
Kentucky
- Equity Medical - Bowling Green- Site Number : 8400240 - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
What the registry record for NCT06687980 still lists
NCT06687980 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Lichen Simplex Chronicus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06687980 names 20 study sites across 12 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06687980 about?
NCT06687980 is a clinical study titled "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)". This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration...
What is the current status of trial NCT06687980?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2024-11-25. Estimated completion is 2026-08-31.
What conditions does trial NCT06687980 study?
This clinical trial studies the following conditions: Lichen Simplex Chronicus.
What interventions are being tested in trial NCT06687980?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06687980?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687980 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Simplex Chronicus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06687980's enrollment target sits among peer trials
138 1577th of 2000 higher than 421 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI